Analytic validation of RNA in situ hybridization (RISH) for AR and AR-V7 expression in human prostate cancer

Clinical Cancer Research

Volumn 22, Issue 18, 2016, Pages 4651-4663

  Guedes, Liana B ^a   Morais, Carlos L ^a   Almutairi, Fawaz ^a   Haffner, Michael C ^a   Zheng, Qizhi ^a   Isaacs, John T ^a   Antonarakis, Emmanuel S ^a   Lu, Changxue ^a   Tsai, Harrison ^a   Luo, Jun ^a   De Marzo, Angelo M ^a   Lotan, Tamara L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR V7; BIOLOGICAL MARKER; STEROID RECEPTOR; UNCLASSIFIED DRUG; RNA ISOFORM; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; DISEASE MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; METASTASIS POTENTIAL; MOLECULAR IMAGING; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA IN SITU HYBRIDIZATION; TISSUE MICROARRAY; VALIDATION STUDY; ANIMAL; BIOLOGY; CANCER GRADING; DISEASE MODEL; GENE EXPRESSION; GENETICS; IMAGE GUIDED BIOPSY; METASTASIS; PROCEDURES; PROSTATE TUMOR; REPRODUCIBILITY; XENOGRAFT;

ANIMALS; BIOMARKERS, TUMOR; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HETEROGRAFTS; HUMANS; IMAGE-GUIDED BIOPSY; IN SITU HYBRIDIZATION; MALE; MICE; NEOPLASM GRADING; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REPRODUCIBILITY OF RESULTS; RNA ISOFORMS;

EID: 84991011417     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0205     Document Type: Article

References (49)

1. Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013;19:43-9.
2. Sadi MV, Barrack ER. Androgen receptors and growth fraction inmetastatic prostate cancer as predictors of time to tumour progression after hormonal therapy. Cancer Surv 1991;11:195-215.
3. Miyamoto KK, McSherry SA, Dent GA, Sar M, Wilson EM, French FS, et al. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993;149:1015-9.
4. Sadi MV, Barrack ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 1993;71:2574-80.
5. Pertschuk LP, Schaeffer H, Feldman JG, Macchia RJ, Kim YD, Eisenberg K, et al. Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab Invest 1995;73:302-5.
6. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Bostwick DG. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol 1999;161:1229-32.
7. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Cheng L, Bostwick DG. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. J Urol 1999;161:1233-7.
8. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004; 28:928-34.
9. Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, et al. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. BJU Int 2008;101:1302-9.
10. Minner S, EnodienM, Sirma H, Luebke AM, Krohn A, Mayer PS, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011;17:5878-88.
11. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77.
12. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.
13. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69: 2305-13.
14. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715-30.
15. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107:16759-65.
16. Lu C, Luo J. Decoding the androgen receptor splice variants. Transl Androl Urol 2013;2:178-86.
17. Sprenger CC, Plymate SR. The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Cancer 2014;5: 207-17.
18. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-25.
19. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castrationresistant prostate cancer cell lines. Cancer Res 2013;73:483-9.
20. Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, et al. Androgen receptor splice variants activating the full-length receptor inmediating resistance to androgen-directed therapy. Oncotarget 2014;5:1646-56.
21. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012;72:3457-62.
22. Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 2014;5: 265-73.
23. Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, et al. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res 2015;43:5880-97.
24. Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, et al. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res 2015;75: 3663-71.
25. Zhao H, Coram MA, Nolley R, Reese SW, Young SR, Peehl DM. Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression. J Urol 2012;188:2158-64.
26. Antonarakis ES, Lu C,Wang H, Luber B, Nakazawa M, Roeser JC, et al. ARV7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38.
27. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 2015;1:582-91.
28. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol 2015;26:1859-65.
29. Onstenk W, Sieuwerts AM, Kraan J, VanM,Nieuweboer AJ, Mathijssen RH, et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 2015;68:939-45.
30. Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. 2015 Apr 23. [Epub ahead of print].
31. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011;6:e27970.
32. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2012;14:22-9.
33. Shi J, Liu H, Ma XJ, Chen Z, He MX, Luo Y, et al. Ribonucleic acid in situ hybridization is a more sensitive method than immunohistochemistry in detection of thyroid transcription factor 1 and napsin A expression in lung adenocarcinomas. Arch Pathol Lab Med 2016;140:332-40.
34. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013;123:4918-22.
35. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003;55:239-46.
36. Sowalsky AG, Xia Z, Wang L, Zhao H, Chen S, Bubley GJ, et al. Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res 2015;13:98-106.
37. Edelstein RA, Carr MC, Caesar R, Young M, Atala A, Freeman MR. Detection of human androgen receptor mRNA expression abnormalities by competitive PCR. DNA Cell Biol 1994;13:265-73.
38. Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett 2006; 580:2294-300.
39. True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, et al. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol 2002;161:705-15.
40. Tsai H, Morais CL, Alshalalfa M, Tan HL, Haddad Z, Hicks JL, et al. Cyclin D1 loss distinguishes prostatic small cell carcinoma from most prostatic adenocarcinomas. Clin Cancer Res 2015;21:5619-29.
41. Takemura R, Takeiwa T, Taniguchi I, McCloskey A, Ohno M. Multiple factors in the early splicing complex are involved in the nuclear retention of pre-mRNAs in mammalian cells. GENES Cells 2011;16:1035-49.
42. Wickramasinghe VO, Laskey RA. Control of mammalian gene expression by selective mRNA export. Nat Rev Mol Cell Biol 2015;16:431-42.
43. Punnoose EA, Ferraldeschi R, Szafer-Glusman E, Tucker EK, Mohan S, Flohr P, et al. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br J Cancer 2015;113:1225-33.
44. Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 2015;7:312re10.
45. de Gramont A, Watson S, Ellis LM, Rodon J, Tabernero J, de Gramont A, et al. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 2015;12:197-212.
46. Custodio N, Carmo-Fonseca M, Geraghty F, Pereira HS, Grosveld F, Antoniou M. Inefficient processing impairs release of RNA from the site of transcription. EMBO J 1999;18:2855-66.
47. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011-25.
48. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-28.
49. Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, et al. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate 2012;72:1491-505.